Session » Infection-Related Rheumatic Disease Poster

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2095

A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients

9:00AM-11:00AM: Abstract Number: 2096

An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2103

Anti-TNF Therapy in Patients with HIV Infection

9:00AM-11:00AM: Abstract Number: 2109

Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study

9:00AM-11:00AM: Abstract Number: 2113

Biological Therapy Is Associated with Faster Recovery and Lower Frequency of Switch Treatment in Patients with Chikungunya Fever

9:00AM-11:00AM: Abstract Number: 2115

BK Polyomavirus Viremia and Viruria in Patients with Autoimmune Connective Tissue Diseases: Impact of Immunosuppressants

9:00AM-11:00AM: Abstract Number: 2123

Clinical Features of Prosthetic Joint Infections in Patients with Rheumatic Diseases vs Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2126

Combined Detection of Cytokines and Biomarkers Improve the Diagnostic Performance of Bacteria Infection in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2099

Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong

9:00AM-11:00AM: Abstract Number: 2107

Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database

9:00AM-11:00AM: Abstract Number: 2127

Diagnosis of Inflammatory Rheumatic Diseases: Preliminary Approach by Urine Metabolomics

9:00AM-11:00AM: Abstract Number: 2098

Distinctive Pattern of LTBI Screening Parameters in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) in Endemic Areas

9:00AM-11:00AM: Abstract Number: 2092

Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials

9:00AM-11:00AM: Abstract Number: 2118

Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2094

Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination

9:00AM-11:00AM: Abstract Number: 2106

Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 2102

First-line Antiretroviral Therapy with Tenofovir Produces Deleterious Effects on Bone and an Increase in Proinflammatory Cytokines Expression After 12 Months of Treatment in Naïve HIV Patients

9:00AM-11:00AM: Abstract Number: 2101

Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 2121

Hospitalization Trends for Bacterial Septic Arthritis in the United States from 1997 to 2014

9:00AM-11:00AM: Abstract Number: 2119

Impact of Day of Admission and Time to Diagnostic Arthrocentesis on Mortality and Other Outcomes in Septic Arthritis: A Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 2117

Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis

9:00AM-11:00AM: Abstract Number: 2110

Invasive Aspergillosis in Rheumatologic Patients in Tertiary Care Hospital in Mexico

9:00AM-11:00AM: Abstract Number: 2120

No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study

9:00AM-11:00AM: Abstract Number: 2122

Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions

9:00AM-11:00AM: Abstract Number: 2112

Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 2125

Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up

9:00AM-11:00AM: Abstract Number: 2114

Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2108

Risk Factors for Pulmonary Nontuberculous Mycobacterial Disease in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2093

Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 2124

Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?

9:00AM-11:00AM: Abstract Number: 2100

Screening for Hepatitis B Surface Antigen and Core Antibody Prior to Administration of Rituximab in Rheumatology Patients

9:00AM-11:00AM: Abstract Number: 2116

Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data

9:00AM-11:00AM: Abstract Number: 2111

Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies

9:00AM-11:00AM: Abstract Number: 2105

The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids

9:00AM-11:00AM: Abstract Number: 2091

The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients

9:00AM-11:00AM: Abstract Number: 2097

Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2104

Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].